Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada

CMAJ. Canadian Medical Association Journal

Volumn 156, Issue 7, 1997, Pages 991-997

  Rivière, Marc ^a   Wang, Shanshan ^a   Leclerc, Caroline ^a   Fitzsimon, Catherine ^a   Tretiak, Roma ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PREDICTION; SECONDARY PREVENTION; STROKE; TIME; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030942919     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Heart disease and stroke in Canada, Ottawa: Heart and Stroke Foundation of Canada; 1995.
2. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332: 512-21.
3. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann Intern Med 1971;74: 1-12.
4. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987;257:2176-80.
5. Tyroler HA. Review of lipid lowering clinical trials in relation to observational, epidemiologic studies. Circulation 1987;76:515-22.
6. Illingworth DR. Management of hyperlipidemia: goals for the prevention of atherosclerosis. Clin Invest Med 1990;13:211-8.
7. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-98.
8. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, et al. Cost and health implications of cholesterol lowering [review]. Circulation 1992;85:1960-8.
9. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
10. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
11. Mathews CK, van Holde KE. Biochemistry. Redwood City (CA): Benjamin/ Cummings Publishing; 1990:623-33.
12. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Lipid Res 1992;33:1569-82.
13. Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995;50:334-63.
14. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. A reappraisal. Drug Saf 1996;14:11-24.
15. European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol 1992;70:1281-6.
16. Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-14.
17. Lambrecht LJ, Malini PL, and the European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholestcrolemia. Acta Cardiol 1993;48:541-54.
18. Ose L, Scott R, and the Simvastatin-Fluvastatin Study Group. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995;10:127-38.
19. Illingworth DR, Stein EA, Knopp RH, Hunninghake DB, Davidson MH, Dujovne CA, et al. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther 1996;1:23-30.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
21. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 1993;71:393-400.
22. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
23. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
24. Kalbfleisch JD, Prentice RL. Statistical analysis of failure time data. New York: John Wiley and Sons; 1980.
25. Collett D. Modeling survival data in medical research. London (UK): Chapman and Hall; 1994.
26. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation 1996;93:1774-6.
27. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
28. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
29. Smurawaska LT, Alexandrov AV, Bladin CF, Norris JW. Cost of acute stroke care in Toronto, Canada. Stroke 1994;25:1628-31.
30. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996;312:1443-8.
31. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
32. Chimowitz MI, Weiss DG, Cohen SL, Starling MR, Hobson RW II. Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167. Stroke 1994;25:759-65.
33. Schulman KA, Lynn LA, Glick HAE, Eisenberg JM. Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.